Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $5.00.
Evercore ISI Remains a Buy on Intellia Therapeutics (NTLA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of ...
FiercePharma18d
It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash
“It’s HUGE!” Evercore's Bayko wrote, a feeling that investors backed up as Madrigal’s share price grew by 16% by the early afternoon on Thursday. In its third-quarter report, Madrigal ...
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate
Evercore ISI downgraded Savara (SVRA, Financials) to "in line" from "outperform," citing worries over Molbreevi's FDA ...
Benzinga.com1y
Liisa Bayko's Stock Ratings
Liisa Bayko is an analyst at Evercore ISI Group. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future ...